Search
for
Sort by
Research 541–570 of 1000+
- Five-alpha-reductase Inhibitors for prostate cancer prevention.
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
- Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
- Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
- Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics
- Differential association between cumulative dose of 5α-reductase inhibitors and mortality
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- Chronic Exposure with 5‐Alpha Reductase Inhibitor Ameliorates Anxiety and Depression‐like Behaviors By Reducing Systemic Oxidative Stress in D‐galactose‐Induced Aging Male Rats
- Chronic Exposure of 5‐Alpha Reductase Inhibitor in Young Male Rats Induces Not Only Metabolic Disturbance, But Also Depressive‐Like Behaviors as Similar with Obese Condition
- The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study
- The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Evidence of Heterogeneity and Quantitative Differences of the Type 1 5α-Reductase Expression in Cultured Human Skin Cells – Evidence of its Presence in Melanocytes
- Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice
- Subcellular localization of the five members of the human steroid 5α-reductase family
- Symptoms of hypogonadism caused by 5α-reductase inhibitors
- Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
- Inhibition of 5α-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation
- Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
- An overview on 5α-reductase inhibitors
- Actions of 5α-reductase inhibitors on the epididymis
- Finasteride: the first 5 alpha-reductase inhibitor.
- Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
- In vivo evidence for an increase in 5alpha‐reductase activity in the rat central nervous system following morphine exposure